CLINICAL PATHWAY FOR ADULT ASTHMA

Slides:



Advertisements
Similar presentations
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Advertisements

or more simply.. -asthma is a condition of paroxysmal reversible airway obstruction which is characterised by : Airflow limitation ( reversible) Airway.
2012 UPDATE. What guidelines do we have available to follow for asthma 1) Asthma GP monitoring Guideline 2) Asthma Diagnosis Guideline 3) Acute asthma.
Presented by Mehrzad Bahtouee, MD Internist, Pulmonologist Assistant Professor of Internal Medicine Boushehr University of Medical sciences.
AsthmaAsthma is a condition characterized by paroxysmal narrowing of the bronchial airways due to inflammation of the bronchi and contraction of the bronchial.
M ANAGING A CUTE A STHMA E XACERBATIONS Cathryn Caton, MD, MS.
2008 Guidelines 2.4 DIAGNOSIS IN ADULTS (1) -based on the recognition of a characteristic pattern of symptoms and signs and the absence of an alternative.
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
Update on Acute Asthma Carlos Camargo, MD, DrPH Emergency Medicine, MGH Channing Laboratory, BWH Harvard Medical School
Acute severe asthma.
Managing acute exacerbations of COPD in primary care.
Asthma Diagnosis Prescribing Acute Management Tracey Bradshaw Respiratory Consultant RIE.
Asthma What is Asthma ? V1.0 1997 Merck & ..
LA CRISI ASMATICA Angelo Corsico Clinica di Malattie dell’Apparato Respiratorio Fondazione IRCCS Policlinico S.Matteo Università di Pavia le urgenze pneumologiche.
Management of Asthma Exacerbations: Key Points n Early treatment is best. Important elements include: – A written action plan n Guides patient self-management.
Ibrahim Tawhari. Prepared by:. Scernario:  Khalid 14 years old come to the clinic c/o shortness of breath for one day duration.  He is a known asthmatic.
ASTHMA: MANAGEMENT AND PREVENTION IN CHILDREN Lecturer: prof. Galyna Pavlyshyn prof. Galyna Pavlyshyn.
Respiratory Failure – COPD and Asthma. 59 year old man presents to the ER with a 3 day history of progressively worsening shortness of breath. He has.
22/06/2011.  Asthma – an introduction (Vanessa)  Diagnosis and management of chronic asthma in line with current BTS guidelines (Dr Lowery)  3 x Case.
1 British Guideline on the Management of Asthma BTS/SIGN British Guideline on the Management of Asthma, May 2008 Introduction Diagnosis Non-pharmacological.
British Guideline on the Management of Asthma. Aims Review of current SIGN/BTS guidelines –Diagnosing Asthma –Stepwise management of Asthma –Managing.
Diagnosing asthma History & Physical examination Measurements of lung function – Spirometry – Peak expiratory flow Measurements of airway hyperresponsiveness.
Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
Case No. 12 SH, 25 years old with a history of asthma since childhood presented to the OPD clinic with complaints of worsening dyspnea and wheezing. He.
MANAGEMENT OF ASTHMA 6 Penaflor, Dominic Quinto, Milraam Ramos,Josefa Victoria Sicat, Gracie Suaco, David Tio- Cuizon, Jeremiah Valenzuela, Virginia Lou.
Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
Asthma Mohammad Ruhal Ain R Ph, PGDPRA, M Pharm (Clin. Pharm) Department of Clinical Pharmacy.
Assessing Control & Adjusting Therapy in Youths > 12 Years of Age & Adults *ACQ values of 0.76–1.4 are indeterminate regarding well-controlled asthma.
1 Asthma October 30, Weiss, Gergen, & Hodgson (1992)2 Pediatric Statistics Prevalence increasing School absences Estimated as more than 10 million.
What would be the most usual abnormal PE finding among asthma suspects? A. Wheezing on auscultation B. Wheezing only on forcible exhalation C. Absence.
Philippine Consensus Report on Asthma Diagnosis and Management 2009.
Acute and chronic management of childhood asthma
1 Pulmonary Function Tests J.B. Handler, M.D. Physician Assistant Program University of New England.
GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.
Component 1: Measures of Assessment and Monitoring n Two aspects: –Initial assessment and diagnosis of asthma –Periodic assessment and monitoring.
Bronchial Asthma By Dr. Zahoor 1. Bronchial Asthma Bronchial Asthma is reversible obstructive lung disease It may be due to chronic air way inflammation.
Component 4 Medications.
Diagnosing and Staging Asthma*
Director, Pediatric Allergy & Immunology
Exacerbations. Exacerbations An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond.
Management of patients with asthma in the emergency department and in hospital Dr. Hassanzadeh Firouzabadi Hospital بيمارستان فيروزآبادي.
Classification of Chronic Asthma Severity on Treatment Domains/EstimatesIntermittentPersistent Mild to Moderate Severe** Daytime symptoms MonthlyWeeklyDaily.
Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:
Maggie Harris Independent Respiratory Nurse Specialist
History Taking Zinc code: UKACL1878ea Date of preparation May 2015 AstraZeneca provided funding & reviewed for technical accuracy.
ASTHMA MANAGEMENT AND PREVENTION PREFACE Asthma affects an estimated 300 million individuals worldwide. Serious global health problem affecting all age.
An Update in Pediatric Asthma DR.NUFOUD AL- SHAMMARI CONSULTANT PEDIATRIC PULMONOLOGIST CHAIRPERSON OF MUBARK AL-KABEER HOSPITAL KUWAIT.
Asthma Guidelines, Diagnosis and Management Alison Hughes Respiratory Specialist Nurse Solent NHS Trust.
Definition of asthma Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory.
© Global Initiative for Asthma GINA Global Strategy for Asthma Management and Prevention 2015 This slide set is restricted for academic and educational.
Helmi Lubis, dr, SpAK Ridwan M. Daulay, dr, SpAK Wisman Dalimunthe, dr, SpA Rini S. Daulay, dr, M.Ked(Ped), SpA.
Definition Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation and a range of pathological changes in the lung.
Asthma 1 د. ميريانا البيضة. DIAGNOSIS 2 3 Definition of asthma.
ASTHMA Definition: Asthma is a chronic lung disease due to inflammation of the airways resulted into airway obstruction. The obstruction is reversible.
Management Of Exacerbations Of Chronic Obstructive Pulmonary Disease D.Anan Esmail Seminar Training Primary Care Asthma + COPD
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
PICH Childhood Asthma project Bina Chauhan Locum GP 4/5/16.
Asthma ( Part 1 ) Dr.kassim.M.sultan F.R.C.P. Objectives: 1-Define asthma 2-Identify its aggravating factors 3-Describe its clinical features 4-Illustrate.
Jessica Case study.
Eileen G. Holland, Pharm.D., BCPS Associate Professor
Managing acute exacerbations of COPD in primary care.
Management of Severe Asthma and COPD
Acute asthma management algorithm
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
APPROACH TO A PATIENT WITH ACUTE SEVERE ASTHMA
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
G IN A lobal itiative for sthma.
Presentation transcript:

CLINICAL PATHWAY FOR ADULT ASTHMA

Clinical Diagnosis of Asthma Variability: Episodic breathlessness, wheezing, cough, chest tightness Precipitation by allergens or non-specific irritants” e.g. smoke, fumes, strong smells or exercise Nocturnal worsening of symptoms Positive family history of asthma & atopic disease Response to appropriate asthma therapy

Physical Examination Findings in Asthma Most usual abnormal PE finding: Wheezing on auscultation – confirms presence of airflow limitation PE: May be normal – because asthma symptoms are variable Wheezing detected only on forced exhalation Wheezing may be absent in severe cases due to severely reduced airflow and ventilation but usually with other signs

Objective measurements in Asthma diagnosis Rationale: Demonstration of reversibility of airflow limitation enhances diagnostic confidence Patients esp. those with long-standing asthma, frequently have poor recognition of symptoms and poor perception of severity Physicians may inaccurately assess dyspnea and wheezing

Lung Function Measurement in Asthma Provides an assessment of severity of airflow limitation, its reversibility and variability Provides confirmation of the diagnosis Provides complementary information about different aspects of asthma control

Spirometry in Asthma Diagnosis of asthma: Spirometry: Degree of reversibility of FEV1 should be >12% and >200ml from pre-bronchodilator value Spirometry: Reproducible but effort-dependent Pre- & post test lacks sensitivity esp. those on treatment, so repeated testing at different visits is advised Proper instructions on maneuver must be given

PEF measurement in Asthma Important in both diagnosis and monitoring Peak flow meters are relatively inexpensive, portable, plastic and ideal for use in home settings for day-to-day objective measurement of airflow limitation Can underestimate degree of airflow limitation particularly in severe cases

PEF measurement in Asthma Can be helpful to confirm the diagnosis of asthma: 60 L/min (or 20% or more pre-BD PEF) improvement after inhalation of a bronchodilator A diurnal variation of >20% (with twice daily readings >10%)

PEF measurement in Asthma Can help to improve asthma control esp. in those with poor perception of symptoms: Self-monitoring using a PEF chart Can help to identify environmental/occupational causes of asthma symptoms: PEF daily or several times a day over periods of suspected exposure to risk factors (at home, workplace, during exercise or other activities)

Controller Medications Inhaled glucocorticosteroids Long-acting inhaled β2-agonists Systemic glucocorticosteroids Leukotriene modifiers Theophylline Cromones Long-acting oral β2-agonists Anti-IgE

Reliever Medications Rapid-acting inhaled β2-agonists Systemic glucocorticosteroids Anticholinergics Theophylline Short-acting oral β2-agonists

Asthma Exacerbations Episodes of progressive worsening of shortness of breath, cough, wheezing or chest tightness or some combination of these symptoms Characterized by significant decreases in PEF or FEV1 which are more reliable indicators of severity of airflow obstruction than degree of symptoms May range from mild to life-threatening

Severity of Asthma Exacerbations Mild Moderate Severe Respiratory Arrest Imminent Breathless Walking Talking At rest Talks in Sentences Phrases Words Alertness May be agitated Usually agitated Drowsy or confused Respiratory rate Increased Often >30/min Accessory muscles & suprasternal contractions Usually not Usually Paradoxical thoraco-abdominal movement Wheeze Moderate, often only end-expiratory Loud Usually loud Absence of wheeze Pulse/min <100 100-120 >120 Bradycardia Pulsus paradoxus Absent <10mmHg May be present 10-25mm Hg Often present > 25 mm Hg PEF after initial BD % predicted or % personal best Over 80% Approx 60-80% <60% predicted or personal best (<100/min or response lasts 2 hrs) PaO2 and/or PaC02 Normal <42 mm Hg < 42 mm hg < 60 mm Hg Possible cyanosis >42 mm Hg possible resp failure Sa02 > 95% 91-95% <90%

Features of Patients at high-risk for asthma-related death Current use of or recent withdrawal from systemic corticosteroids Emergency care visit for asthma in the past year History of near-fatal asthma requiring intubation or mechanical intubation Not currently using inhaled steroids Overdependence on rapid acting inhaled β2-agonists, esp. those with more than one canister monthly Psychiatric disease or psychosocial problems, incl. the use of sedatives Noncompliance with asthma medication plan

Management of Asthma Exacerbations Treatment of exacerbations depends on: The patient Experience of health care professional Therapies that are the most effective for the particular patient Availability of medications Emergency facilities

Treatment of Exacerbations The aims of treatment are to: Relieve airway obstruction as quickly as possible Relieve hypoxemia Restore lung function to normal as early as possible Plan and avoidance of future relapses Develop a written action plan in cases of future exacerbations

Management of Asthma Exacerbations Primary therapies for exacerbations: Repetitive administration of rapid-acting inhaled β2-agonists Early introduction of systemic glucocorticosteroids Oxygen supplementation Closely monitor response to treatment with serial measures of lung function

Criteria for Hospitalization Inadequate response to therapy within 1-2 hours Persistent PEF <50% after 1 hour of treatment Presence of risk factors Prolong symptoms prior to ER consult Inadequate access to medical care and medications Difficult home condition Difficulty in obtaining transport to hospital in event of further deterioration

Asthma Exacerbations and Hospitalization Despite appropriate therapy ~10 to 25% of ER patients with acute asthma will require hospitalization The response to initial treatment in the ER is a better predictor of the need for hospitalization than is severity on presentation FEV1 or PEF appears to be more useful in adults for categorizing severity of exacerbation and response to treatment

Management of Acute Exacerbations: Hospital Setting Initial Assessment: History, PE, PEF or FEV1, Sa02 PEF or FEV1 >40% predicted (Mild to Moderate) Oxygen to achieve Sa02 >90% Inhaled SABA by nebulizer or MDI with valve holding chamber up to 3 doses in 1st hour PEF or FEV1 <40% predicted (Severe) Oxygen to achieve Sa02 >90% High dose inhaled SABA + Ipratropium by nebulizer or MDI with valve holding chamber every 20 min or continuously for 1 hour Impending or actual respiratory arrest Intubation and mechanical ventilation with 100% 02 Nebulized SABA and Ipratropium Intravenous corticosteroids Consider adjunct therapies Repeat Assessment: PE, PEF, Sa02, other tests as needed Admit to hospital intensive care -see below Moderate Exacerbation: PEF or FEV1 -40-69% predicted or personal best PE: moderate symptoms Treatment: Inhaled SABA every 60 mins Oral systemic corticosteroids Continue treatment 1-3 hrs provided there is improvement: make decision in < 4 hours Severe Exacerbation: PEF or FEV1 < 40% predicted or personal best PE: Severe symptoms at rest, accessory muscle use, chest retraction History: high-risk for asthma related death No improvement after initial treatment Treatment: Oxygen Nebulized SABA+Ipratropium hourly or continuous Oral systemic corticosteroids Consider adjunct therapies

Management of Acute Exacerbations: Hospital Setting CONTINUATION Moderate exacerbation Severe Exacerbation Good Response Response sustained for 1 hr after last treatment No risk factors S/Sx: no distress, normal PE PEF > 70% predicted or personal best Sa02 >90% Incomplete Response Within 1 hr &/or (+) risk factors S/Sx: mild to moderate PEF or FEV1 40-69% predicted or personal best Sa02 not improving Poor Response Within 1 hr &/or (+) risk factors S/Sx: severe drowsiness, confusion PEF < 40% predicted or personal best ABG: paC02 >42mm Hg Individualize decision re: hospitalization Discharge Home Continue inhaled SABA Continue oral steroids Consider initiation of ICS Patient education: Review medications, including inhaler technique Review/ initiate action plan Recommend close medical follow-up Admit to ICU: Continue inhaled SABA+ inhaled anti-cholinergic Consider SQ,IV or IM B2-agonist IV steroids IV aminophylline Continue oxygen Possible intubation/mechanical ventilation Admit to Hospital Oxygen Inhaled SABA Systemic (oral or IV) corticosteroids Consider adjunct therapies Monitor vital signs, FEV1, PEF saO2 IMPROVE Discharge Home ( see below) improve

Criteria for ICU Admission Lack of response to initial therapy in ER Presence of confusion, drowsiness, other signs of impending arrest or loss of consciousness Impending respiratory arrest: PaO2 < 60 mmHg on supplemental oxygen PaCO2 > 45 mmHg

Management of Acute Exacerbations: Hospital Setting CONTINUATION Admit to Hospital IMPROVE Discharge home -Continue inhaled SABAs Continue oral systemic steroids Continue on ICS Patient education: Review medications, including inhaler technique Review/ initiate action plan Recommend close medical follow-up Before discharge, schedule follow-up appointment with primary care provider and/or asthma specialist in 1-4 weeks.

Key FEV- Forced Expiratory Volume in 1 second ICS- Inhaled Corticosteroids PCo2- Partial pressure Carbon Dioxide PEF- Peak Expiratory Flow SABA- Short Acting Beta2 agonist SaO2- Oxygen Saturation

ADDITIONAL PATIENT EDUCATION Home Assessment

Management of Asthma Exacerbations: Home Treatment Assess Severity Initial Treatment Inhaled SABA: up to two treatment 20 min apart of 2-6 puffs of MDI or nebulizer treatment Good Response No wheezing or dyspnea PEF > 80% predicted or personal best Contact clinician for follow-up Instructions & further management May continue inhaled SABA over 3-4 hrs for 24-48 hrs Consider short course of oral systemic corticosteroids Incomplete Response Persistent wheezing & dyspnea (tachypnea) PEF 50-79% predicted or personal best Add oral systemic corticosteroids Continue inhaled SABA Contact clinician urgently (this day) for further instructions Poor Response Marked Wheezing & dyspnea PEF <50% predicted or personal best Add oral systemic corticosteroids Report inhaled SABA immediately If distress is severe & non-responsive to initial treatment: call your doctor AND ambulance transport To ER

REFERENCE Philippine Concensus Report on Asthma Diagnosis and Management 2009 by PCCP Council on Bronchial Asthma

PREPARED BY: COORDINATED WITH: Section of Pulmonary Medicine Emergency Department